Skip to main content

Table 3 Risk factors of endocrine disorders in young children with thalassemia major

From: Detection of endocrine disorders in young children with multi-transfused thalassemia major

  Endocrine disorder
(28/120)
No endocrine disorder
(92/120)
Odds ratio (95% confidence interval) P value
Age mean (SD) 11.60 (3.21) 11.01 (1.27) 1.33 (0.48:2.21) 0.90
Gender
 Females 12 (42.86%) 42 (45.65%) 1  
 Males 16 (57.14%) 50 (54.35%) 1.12 (0.48:2.63) 0.80
Duration of the disease/years Mean (SD) 6.22 (1.20) 5.28 (2.64) 1.20 (0.98:1.45) 0.07
Malnutrition
 No 12 (42.86%) 24 (26.09%) 1  
 Yes 16 (57.14) 68 (73.91) 0.47 (0.19:1.14) 0.09
Hemoglobin level before blood transfusion (Gram/DL) Mean (SD) 7.12 (1.62) 6.69 (1.89) 1.14 (0.90:1.46) 0.29
Splenectomy
 No 13 (46.43%) 52 (56.52%) 1  
 Yes 15 (53.57%) 40 (43.48%) 1.50 (0.64:3.50) 0.35
Family history of thalassemia major
 No 13 (46.43%) 33 (35.87%) 1  
 Yes 15 (53.57%) 59 (64.13%) 0.64 (0.27:1.51) 0.65
Family history of endocrine disorders
 No 15 (53.57%) 58 (63.04%) 1  
 Yes 13 (46.43%) 34 (36.96%) 1.48 (0.63:3.48) 0.37
Ferritin level Mean (SD) 3631.45(1636) 2658.40 (1443) 0.98 (0.96–0.99) 0.003
Deferasirox
 No 16 (57.14%) 68(73.91%) 1  
 Yes 12 (42.86%) 24 (26.09%) 2.13 (0.88:5.13) 0.09
Desferoxamine
 No 21 (75.00%) 74 (80.43%) 1  
 Yes 7 (25.00%) 18 (19.57%) 1.37 (0.50:3.72) 0.54
Combined therapy
 No 19 (67.86%] 42 (45.65%) 1  
 Yes 9 (32.14%) 50 (54.35%) 0.40 (0.16:0.97) 0.04
Compliance to medication
 Received ≤50%/month 19 (67.86%] 41(44.57% 1  
 Received > 50/month 9 (32.14%) 51 (55.43% 0.38 (0.16:0.93) 0.03
  1. P value was obtained from univariate logistic regression